<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00089557</url>
  </required_header>
  <id_info>
    <org_study_id>C114</org_study_id>
    <nct_id>NCT00089557</nct_id>
  </id_info>
  <brief_title>An Open-Label Extension Study of NGX-4010 for the Treatment of Neuropathic Pain</brief_title>
  <official_title>An Open-Label Extension Study of NGX-4010 for the Treatment of Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeurogesX</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeurogesX</source>
  <brief_summary>
    <textblock>
      This study is an open-label, multicenter, extension study for subjects who completed&#xD;
      NeurogesX Study C111 and received treatment with NGX-4010 (Capsaicin Patch) within 12 weeks&#xD;
      (up to +7days) before entry into Study C114&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Herpes Zoster</condition>
  <condition>Neuralgia</condition>
  <condition>Pain</condition>
  <condition>HIV Infections</condition>
  <condition>Peripheral Nervous System Diseases</condition>
  <condition>Diabetic Neuropathies</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Polyneuropathies</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capsaicin Dermal Patch</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Eligibility Criteria:&#xD;
&#xD;
          -  Must have completed NeurogesX Study C111 and received treatment with NGX-4010&#xD;
             (Capsaicin Patch) within 12 weeks (up to +7 days) before entry into Study C114.&#xD;
&#xD;
          -  Demonstrated adherence to protocol requirements during Study C111, and willing and&#xD;
             able to comply with protocol requirements for the duration of the study participation.&#xD;
&#xD;
          -  Must not have had any serious adverse experience since enrollment in Study C111,&#xD;
             whether or not considered to be study drug-related.&#xD;
&#xD;
          -  Must have intact skin at the treatment area.&#xD;
&#xD;
          -  Must be prepared to remain on the same pain medications at the same doses as before&#xD;
             the study for the entire duration of the study (36 weeks).&#xD;
&#xD;
          -  Must not use topical pain medications on painful areas.&#xD;
&#xD;
          -  Must be at least 18 years old, not pregnant, and able to take care of self&#xD;
             independently, with only occasional assistance if needed.&#xD;
&#xD;
          -  No history or current problem with substance abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2004</verification_date>
  <study_first_submitted>August 6, 2004</study_first_submitted>
  <study_first_submitted_qc>August 6, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2004</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Dermal assessment</keyword>
  <keyword>Pain assessment</keyword>
  <keyword>Diary</keyword>
  <keyword>Analgesics</keyword>
  <keyword>Capsaicin</keyword>
  <keyword>Herpes zoster</keyword>
  <keyword>Neuralgia</keyword>
  <keyword>Pain</keyword>
  <keyword>HIV Infections</keyword>
  <keyword>Peripheral Nervous System Diseases</keyword>
  <keyword>Diabetic Neuropathies</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Polyneuropathies</keyword>
  <keyword>Complementary Therapies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capsaicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

